Business Overview
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies for blood coagulation disorders, with lead asset sutacimig (HMB-001) in Phase 1/2 clinical development for Glanzmann thrombasthenia and Phase 2 for Factor VII deficiency, and HMB-002 in Phase 1/2 for Von Willebrand Disease. The company completed a corporate reorganization on March 30, 2026, converting from a Danish ApS structure to a Delaware corporation, and subsequently completed an IPO in May 2026 raising approximately $317.2 million in net proceeds.
Forward Guidance
"The Company believes that its existing cash, cash equivalents, and marketable securities, together with the net proceeds from the IPO of approximately $317.2 million, will enable it to fund its operating expenses and capital expenditure requirements for at least one year from the date of the issuance of these unaudited condensed consolidated financial statements." The company expects operating losses and negative cash flows to continue for the foreseeable future as it continues development of product candidates.
Key Risk Factors
The company has incurred significant losses since inception with no approved products and expects continued significant losses for the foreseeable future. Clinical development is lengthy, expensive, and uncertain, with serious adverse events of thrombosis identified in sutacimig development, requiring potential abandonment or limitation of product candidates. The company is heavily dependent on the success of its only two clinical-stage candidates (sutacimig and HMB-002) and requires substantial additional funding; failure to raise capital on acceptable terms could force delays or elimination of programs. Substantial reliance on third parties for clinical trials and manufacturing creates performance and compliance risks, and competition is substantial in the biotechnology space. The company has identified material weaknesses in internal controls over financial reporting that, if not remedied, could prevent timely and accurate financial statements.
